Osteolytic Bone Lesions Of Multiple Myeloma

Osteolytic Bone Lesions Of Multiple Myeloma – General Information

Osteolytic Bone Lesions Of Multiple Myeloma is a malignant growth of the bodily fluid cells which causes damage of the osseous system. It is the most frequent tumor of the connective tissues and it generally affects the skull, the spine, the ribs, the pelvis and the sternum; it can also alter any bone with red marrow. The most common patients are about sixty years old and there is a known fact that men are more likely to suffer of this disease than women. The radiological image of Osteolytic Bone Lesions Of Multiple Myeloma is described by asymmetrical lytic flaws of different sizes. These present no periosteal response and they are, most of the time, called “punched out”. The chemical process of erosion begins in the medullar system and advance to the cortex. In some cases, the bones do not present an increased level of consumption; this means that you should do a skeletal survey. On a detailed examination, you will find out that the marrow space was substitute by a distributed gelatin like brown red tissue and it is likely to observe tumor nodules of about 1, 5 cm. Microscopically, Osteolytic Bone Lesions Of Multiple Myeloma is constituted of pieces of plasma cells.
In the last years, there was noticed an increase in the number of the cases reported; though, there are huge differences from a region to other. For example, in the U.S.A there are about 16,000 new cases each year, while in the Europe, the number is higher, about 19,500.

Osteolytic Bone Lesions Of Multiple Myeloma- Symptoms

Osteolytic Bone Lesions Of Multiple Myeloma – Treatment

For treating Osteolytic Bone Lesions Of Multiple Myeloma, doctors usually recommend bisphosphonates like zoledronic acid and pamidronate; in what concerns the patients with lytic lesion of bones they are advised to utilize intravenous pamidronate. Once the sufferer chooses to start the treatment, he must continue until he notices an improvement or, in the worst case, until his condition is getting worst. Anyway, there are no evidences of what can happen if the patient stops taking the drugs. In most of the cases of Osteolytic Bone Lesion Of Multiple Myeloma it is considered reasonable for patients to start taking intravenous bisphosphonates even if there are no certain proofs of lytic bone lesions. Anyway, one should not do that if he is diagnosed with indolent or smoldering myeloma or with solitary plasmacytoma. In addition to these drugs, doctors use radiation therapy, surgical intervention or analgesics in order to stabilize or to impend lesions.

In treating Osteolytic Bone Lesions Of Multiple Myeloma another important part belongs to chemotherapy and radiotherapy. As results show, the condition of a patient who followed chemotherapy did not change too much, thus the bone resorption decreased by 30% and the level of proteins remained the same. All these considered, it is extremely necessary to find a new therapy for treating the lesions of the bones. The drugs for inhibiting the evolution of this disease are: bisphosphonate compounds, etidronate, clodronate, pamidronate and they are available for selling in most of the regions, especially in America and Europe. If you decide to use bisphosphonate compounds for treating Osteolytic Lesions Of Multiple Myeloma, they will be given in exalted doses, bigger than when treating Osteoporosis. Furthermore, these substances lack in oral absorbability but, on the other hand, the use of large quantities can result in merely noticeable side effects, such as gastrointestinal illness: diarrhea, retching, abdominal pain, hypocalcemia, allergic reactions and some mental difficulties like insomnia. In these conditions, the bisphosphonate substances are given to sufferers only when the intravenous drips or the injections are unavailable.

From another point of view, these compounds are given permanently in order to sustain the effects. On the other hand, the bisphosphonate compound named hereinafter (1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid) is considered to subdue the bone resorption, the cancer, the hypercalcemia, the Osteoporosis, the rheumatoid arthritis; the results do not clearly mention the effects of this compound in what concerns Osteolytic Bone Lesions Of Multiple Myeloma. In contradiction to this, a study lead by mistake, showed that this substance can inhibit the evolution of this disease and it can be used for treating bone fractures. The composition of this drug allows it to be used at the same time with anticancer agents like chemotherapeutics. When observing immunoglobulin cells which show the evolution of the disease, the compounds of this medicine proved to be safe for optional administration, together with radiotherapy and chemotherapy. The difference between this substance and other bisphosphonate compounds is the fact that, during administration, the quantity of the doses will decrease. Specialists also assume that a more beneficial result will be obtained in the treatment of Osteolytic Bone Lesions of Multiple Myeloma if combining this substance with other anticancer compounds.